Fri, November 3, 2017
Thu, November 2, 2017
Wed, November 1, 2017
Tue, October 31, 2017
Mon, October 30, 2017
Fri, October 27, 2017
Thu, October 26, 2017

Matthew Luchini Maintained (BLUE) at Buy with Increased Target to $162 on, Oct 30th, 2017


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-162-on-oct-30th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Increased Target from $134 to $162 on, Oct 30th, 2017.

Matthew has made no other calls on BLUE in the last 4 months.



There are 6 other peers that have a rating on BLUE. Out of the 6 peers that are also analyzing BLUE, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Biren Amin of "Jefferies" Downgraded from Strong Buy to Hold on, Wednesday, October 11th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $109 on, Thursday, July 27th, 2017
  • Dane Leone of "BTIG" Downgraded from Strong Buy to Hold on, Friday, June 30th, 2017


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Josh Schimmer of "Evercore ISI Group" Upgraded from Hold to Buy on, Monday, October 16th, 2017
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell on, Monday, October 2nd, 2017
  • Gena Wang of "Barclays" Initiated at Buy and Held Target at $151 on, Thursday, September 7th, 2017

Publication Contributing Sources